Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News NervGen Pharma Corp NGENF


Primary Symbol: V.NGEN

Healthcare Biotechnology
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSXV:NGEN)

NervGen Announces "At-The-Market" Equity Program

Newsfile 5 days ago

NervGen Pharma Reports Q3 2024 Financial Results and Operational Updates

Newsfile November 14, 2024

NervGen Pharma to Present at the Stifel 2024 Healthcare Conference

Newsfile November 7, 2024

NervGen Pharma Provides Update on Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

Newsfile September 30, 2024

NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th Annual Science & Advocacy Symposium Focused on Spinal Cord Injury

Newsfile September 20, 2024

NervGen Pharma to Present at the 63rd International Spinal Cord Society Annual Scientific Meeting

Newsfile September 16, 2024

NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Newsfile August 27, 2024

NervGen Pharma Reports Q2 2024 Financial Results and Operational Updates

Newsfile August 22, 2024

NervGen Pharma to Present at the Canaccord Genuity 44th Annual Growth Conference

Newsfile August 6, 2024
View More News ››

Opinion & Analysis (TSXV:NGEN)

NervGen Pharma: Proof that NVG-291 works?

Knox Henderson 2 days ago

NervGen: Are amazing human trial results leaking out?

Knox Henderson July 2, 2024

Can NervGen keep a lid on explosive news?

Knox Henderson March 20, 2024

Is this stunning 'evidence' that NervGen has the goods?

Knox Henderson February 1, 2024

NervGen Pharma: A “Blockbuster Drug” in the Making?

Stockhouse Editorial June 28, 2021

Alzheimer’s Breakthrough: Why the Experts are Betting on NervGen

Stockhouse Editorial April 7, 2021
View More Opinion ››

Bullboard Posts (TSXV:NGEN)

NervGen Pharma to Present at the Canaccord Genuity 44th Annu

News; $NGENF NervGen Pharma to Present at the Canaccord Genuity 44th Annual Growth ConferenceVancouver, British Columbia--(Newsfile Corp...
whytestocks - August 6, 2024

RE:RE:Stock options

who cares, you either own it and win with them, or lose with them. Stock is do or die, under .50 cents if drug shows no results, so the...
Nosleep - July 11, 2024

RE:Stock options

VERY TACKY !! Gutless move by weak gutless Board. 
wallpaper2 - July 10, 2024

2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS

NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium   V.NGEN | 6...
greenland - June 26, 2024

Stock options

The issuance of stock options does not inspire confidence as these options were given away at cost, with no premium in them. I would...
deepoil0808 - June 7, 2024

Safest strategy is to WAIT for results first...then decide.

This stock is a BINARY stock, meaning will be very volatile when results are released. Best strategy is to wait for trial results before...
deepoil0808 - June 5, 2024
View more Bullboard ››

Calima Energy Ltd

Calima Energy Ltd

Calima Energy Limited is an Australia-based production-focused energy company. The Company is engaged in the exploration and ...
View More »